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Natural killer (NK) cells are powerful eﬀector cells that can be directed to eliminate tumor cells through tumor-targeted
monoclonal antibodies (mAbs). Some tumor-targeted mAbs have been successfully applied in the clinic and are included in the
standard of care for certain malignancies. Strategies to augment the antitumor response by NK cells have led to an increased
understandingofhowtoimprovetheireﬀectorresponses.Next-generationreagents,suchasmolecularlymodiﬁedmAbsandmAb-
cytokine fusion proteins (immunocytokines, ICs) designed to augment NK-mediated killing, are showing promise in preclinical
and some clinical settings. Continued research into the antitumor eﬀects induced by NK cells and tumor-targeted mAbs suggests
thatadditionalintrinsicandextrinsic factorsmayinﬂuencetheantitumorresponse.Therefore moreresearch isneeded thatfocuses
on evaluating which NK cell and tumor criteria are best predictive of a clinical response and which combination immunotherapy
regimens to pursue for distinct clinical settings.
1.Introduction
Natural killer (NK) cells are innate immune eﬀector cells
capable of recognizing and destroying virally infected
and neoplastic cells. The importance of NK cell-mediated
immunosurveillanceinthecontroloftumorgrowthhasbeen
evaluated in NK cell-deﬁcient mouse models with limited
information in humans. Humans with NK cell deﬁciencies
are plagued with persistent acute viral infections, especially
herpes simplex virus [1]. However, mouse models with
defects in NK cell eﬀector function clearly demonstrate an
increased susceptibility to neoplastic disease as they age [2].
NK cell eﬀector functions can be exploited for the
treatment of some tumors through their ability to mediate
antibody-dependent cellular cytotoxicity (ADCC). The
NK cell Fc receptor, CD16 (FcγRIIIa), contains an
immunotyrosine-activating motif(ITAM)inthecytoplasmic
domain. NK cell recognition of an antibody-coated target
cell results in rapid NK cell activation and degranulation
[3]. mAbs that speciﬁcally target tumor cells take advantage
of the ADCC eﬀector pathway to tip the balance of an
interrogating NK cell in the favor of the activating receptors
resulting in tumor cell destruction and an anti-tumor
immune response [4].
Tumor-targeted mAbs that initiate NK cell ADCC
have been used clinically. Antibodies targeting CD20,
Her2/neu, epidermal growth factor receptor (EGFR), and
disaloganglioside (GD2) are examples of clinically suc-
cessful antibodies whose mechanisms include NK cell-
mediated ADCC [5–9]. GD2 is overexpressed on tumors
of neuroectodermal origin, such as neuroblastoma and
melanoma, and minimally expressed in normal tissues mak-
ing it a good target for tumor-speciﬁc mAb. Anti-GD2 mAbs
work through NK cell-mediated ADCC and have demon-
strated clinical beneﬁt for children with neuroblastoma [10].
In thispaper, we will use examplesfrommAbstargetingGD2
and other tumor antigens to discuss antibody-facilitated NK
cell-mediated cancer immunotherapy strategies.2 Journal of Biomedicine and Biotechnology
2.NK CellResponsesto Tumor-SpeciﬁcmAbs
There are numerous Fc receptors for IgG (FcγR) that are
widely expressed on immune cells. The FcγR family consists
of four classes of receptors, FcγRI, FcγRII, FcγRIII, and
FcγRIV, that have been identiﬁed in both mice and humans.
There are signiﬁcant similarities in the functions of the
FcγR receptors between mice and humans, but there is
limited homology in receptors themselves [11]. To date,
only one inhibitory FcγR, FcγRIIb, has been identiﬁed and
is the only receptor to have complete homology between
mice and humans [11]. FcγRs can be found on virtually
all hematopoietic cells except T cells; in most cases, cells
coexpress activating and inhibitory FcγR, allowing for the
balance between activating and inhibitory receptors to
dictate their response [11]. NK cells are an exception to this
ruleand expressonlythe activating FcγRIIIa.NKcellsdonot
express the inhibitory FcγRIIb.
Because of their rapid and unopposed responses to mAb,
NKcells play a major role in the anti-tumor response elicited
bytumor-speciﬁc mAbs. Early studiesdemonstratedthatNK
cells are the primary mediators of the immune response
elicited by tumor-targeted mAbs. However, recent data show
that granulocytes may also play a signiﬁcant role in anti-
tumor responses generated by tumor-targeted antibodies
[11, 12]. NK cells are important eﬀectors in the mAb-
driven immune response to tumors, and data continue to
accumulate on their importance [13]. Multiple clinically
successful mAbs utilizeNK-mediatedADCCas amechanism
of action. Rituximab (anti-CD20), Herceptin (anti-Her-
2/neu), Cetuximab (anti-EGFR), and the anti-GD2-mAbs
3F8and ch14.18 are examples oftumor-speciﬁc mAbswhose
clinical activity can be attributed, at least in part, to NK cells.
3.AugmentationofmAbResponsesthroughthe
ActivationofNKCells
Various strategies of NK cell activation alongside antibody
administration have been evaluated. NK cell activation
can occur through a variety of stimuli including cytokine
administration, toll-like receptor (TLR) agonists, or agonist
antibodies directed toward activating receptors on NK
cells. The coadministration of an NK-activating cytokine,
interleukin-2 (IL-2), enhances the anti-tumor activity of
NK cells [14, 15]. The TLR9 agonist CpG can activate
numerous innate immune eﬀectors, including NK cells
[16]. Combination of CpG with Rituximab increases NK-
mediated ADCC in vitro and anti-tumor responses in a
mouse model of CD20-expressing tumors [17].
Further activation of NK cells through numerous recep-
tors including 4-1BB or the Fc receptor FcγRIIIa increases
ADCC activity [18]. Antibodies with Fc regions that have
higher aﬃnity for FcγRIIIa are better at activating NK
cells while simultaneously initiating additional NK eﬀector
pathways [19]. High-aﬃnity Fc-antibodies can be used
at lower concentrations than traditional antibodies and
maintain anti-tumor activity [19]. Antibodies with higher
aﬃnity for FcγRIIIa may be beneﬁcial in a clinical setting
by reducing the amount of antibody necessary to produce
an antitumor response and therefore reduce mAb-related
toxicities [20]. 4-1BB (CD137) is an activating receptor on
the surface of NK cells [21]. The activation of NK cells
with an agonistic antibody to 4-1BB has recently been
described in a mouse model of B-cell lymphoma [18]. 4-
1BB is increased on CD56dim eﬀector NK cells after CD16-
mediated activation. Activation of NK cells with a 4-1BB
agonist antibody between Rituximab courses in vivo led
to complete regression of subcutaneous murine lymphoma
tumors by NK cells [18].
The combination of mAb therapy with cytokines is
another strategy used to increase their activity. Combination
of Herceptin with interleukin-12 (IL-12), an important
cytokine to NK cell responsiveness and IFNγ production,
increases the response of NK cells to Her2-expressing breast
tumor cells in a mouse model of breast cancer [22]. Clinical
development of this concept is underway [23]. Augmenta-
tion of NK cell responses by the addition of exogenous IL-2
hasbeenextensivelydemonstratedtoincreasetheanti-tumor
response of antibody therapy. IL-2-activated lymphokine-
activated killer (LAK) cells have increased ADCC activity
against mAb-coated tumor cells [14, 15, 24]. IL-2 lowers
the required amount of antibody necessary for NK cells to
eﬀectivelylyse antibody-coated tumortargets[25].Increased
NK cell eﬀector function after IL-2 activation is true of NK
cells isolated from humans, mice, and dogs [26, 27].
4. Altered mAbs That Increase NK Cell Effector
Functions
Following the production of the initial 14.18 murine anti-
GD2 mAb, several molecular modiﬁcations have resulted in
2nd and 3rd generation reagents, designed to have improved
f u n c t i o n .F i r s t ,t h e r ew a st h ec l a s ss w i t c ht om u r i n eI g G 2 a
to augment ADCC (creating the 14.G2a mAb). This was
followed the by creation of a chimeric antibody (ch14.18),
a humanized antibody (hu14.18), and multiple altered
hu14.18antibodies toenhance the anti-tumor response [10].
Humanized anti-GD2 mAb hu14.18K322A (K322A) is a
new-generation anti-GD2 mAb that has been designed to
stimulate NK cell eﬀector mechanisms and simultaneously
reduce some of the toxicities associated with anti-GD2
therapy [5]. hu14.18K322A has two key diﬀerences from its
hu14.18 parent. First, hu14.18K322A was produced in a rat
hybridomaline,YB2/0.YB2/0cellshavelowfucosyltrasferase
activity and therefore produce antibodies with fewer fucose
side chains on the Fc portion. IgG antibodies that have low
or absent fucose side chains are more eﬀective at eliciting
ADCC[28,29].Second,hu14.18K322Ahasapointmutation
at the 322 position resulting in the replacement of lysine 322
with an alanine. This speciﬁc mutation reduces the ability
of hu14.18K322A to activate complement compared to its
anti-GD2 relatives [30]. Allodynia, the major clinical toxicity
associated with anti-GD2 therapy, is likely the result of
complement ﬁxation. Therefore, hu14.18K322A is designed
to retain or potentially enhance NK-mediated anti-tumor
responses while reducing the antibody’s toxicity [30].Journal of Biomedicine and Biotechnology 3
Immunocytokines (ICs) are antibodies with linked
cytokines at the Fc terminal end. The anti-GD2 IC hu14.18-
IL-2 is a humanized mAb with two functional interleukin-
2 proteins at the Fc terminal end [31, 32]. ICs may have
certain advantages over traditional mAbs [33]. In several
preclinical models, using 3 diﬀerent ICs, the IC provided
far greater antitumor eﬀects than the same amount of the
naked mAb infused with the same amount of IL2 (but
infused simultaneously as separate molecules rather than as
the IC fusion protein). This may be because ICs transport
cytokine to the site of tumor and can support an ongoing
local anti-tumor immune response [34, 35]. Direct delivery
of IC into the tumor itself elicits a more potent local eﬀect.
Intratumoral injection of IC in tumor-bearing mice induces
better antitumor responses than systemic administration.
This eﬀect can be attributed to its activating eﬀects on
intratumoral NK cells [34].
One advantage of using IC is its eﬀect on the formation
ofanimmune synapse betweentheAb-coatedtumorcelland
the NK cell. Recent data from our laboratory suggest that
NK recognition of an IC involves not only the Fc receptor,
but also IL2 receptors [36, 37]. The involvement of the
IL2R increases IC-facilitated conjugate formation between
NK cells and tumor cells (Figure 1)[ 36, 37]. Furthermore,
IC may facilitate NK: tumor cell conjugation in the absence
of Fc receptors. Using an NK cell line with minimal, if
any, expression of FcγRIIIa, we recently demonstrated that
the IL2Rα chain plays an important role in NK: tumor cell
conjugation [36]. The association of NK cells with IC-coated
tumor cell results in the formation of an activated immune
synapse (AIS), deﬁned by the localization of LFA-1and CD2
[37]. AIS formation facilitated by an IC is hallmarked by
clustering of NK cell CD25 into the synapse and can also be
abrogated by CD25 blockade [37]. The potential beneﬁt of
IL-2 containing ICs in activating and assisting NK cells in
tumor cell destruction is a relatively new research area for
clinical NK-mediated tumor immunotherapy.
5.Recent Clinical Results with Anti-GD2 mAb-
Induced ADCC
High-risk childhood neuroblastoma remains a disease that
has not shown major improvements in cure rates over
the past 2 decades [38]. Preclinical and early clinical work
suggested that anti-GD2-based mAb therapy would be
most eﬀective if given in the setting of minimal residual
disease, and in combination with cytokines that augment
ADCC. A large randomized study was conducted by the
Children’s Oncology Group (COG) to test these concepts.
Following initial response to combined agent chemotherapy,
surgery, ablative chemotherapy, and autologous hematopoi-
etic stem cell transplant, children received isotretinoin and
were randomized to receive immunotherapy (the ch14.18
chimeric mAb + IL2 + GM-CSF) or no immunotherapy.
Two-hundred twenty-six children were randomized, and the
group receiving immunotherapy showed a 2-year event-
free survival of 66% versus 46% for the no-immunotherapy
group (P = .012) [39]. In the USA, through the COG, this
immunotherapy regimen has thus become the “standard of
care” maintenance treatment for high-risk patients that have
responded to their initial therapy.
The next-generation immunotherapy approach has
involved the hu14.18-IL2 IC. Our hypothesis, based on our
preclinical data [27], was that the IC approach would work
best forchildrenwith smaller amountsofrefractory/relapsed
neuroblastoma. A recent phase II COG study in children
with relapsed or refractory neuroblastoma showed that 7
of 24 patients with “nonbulky” disease showed evidence of
antitumor activity, while 0 of 13 with bulky disease had evi-
dence of antitumor activity [40]. The results of this study are
consistent with the hypothesis of better activity for nonbulky
disease (P = .03). We are continuing to develop this agent
and are hoping that a future large COG trial will enable us
to test this genetically engineered molecule for children in
remission in order to prevent relapse, as was done for the
separate ch14.18 mAb with GM-CSF and IL2 regimen [39].
6.Fc ReceptorPolymorphisms and NK
Responses to mAbs and ICs
Two allelic polymorphisms have been identiﬁed in human
FcγRIIIa at position 158. The aa at this location in the
receptor interacts with the hinge region of IgG antibodies
and aﬀects the magnitude of response at subsaturating
concentrations of IgG [41]. The one aa diﬀerence of either
a phenylalanine (f) or a valine (v) in FcγRIIIa may have
implications for mAb therapy [42]. NK cells containing a
valine at position 158 have a higher aﬃnity for IgG. NK
cells isolated from individuals bearing this receptor contain
more cytophilic IgG when examined directly ex vivo [42].
FcγRIIIa158v is associated with a less favorable prognosis
for autoimmune suﬀerers [43]. FcγRIIIa158v NK cells are
more sensitive to activation and have a higher calcium inﬂux
and more rapid induction of activation-induced cell death
(AICD) when stimulated [44]. A more sensitive activating
receptorthatproducesa strongerintracellularresponse, such
as Ca2+ inﬂux, may support a more productive immune
synapse by localizing granules faster to the centrosome, as
has been shown with T-cell responses to TCR stimulation
[45]. Faster granule localization results in more granules
loaded into the synapse for target cell destruction [45].
Therefore, NK cells with FcγRIIIa158v receptors may have a
twofold advantage in the setting of mAb-mediated cancer
immunotherapy: (1) enhanced ability to recognize and bind
to tumorcells coatedwith mAbmoleculesand (2)the release
of more granules for each tumor cell they encounter.
Patients with an FcγRIIIa158v genotype respond better
to therapy that utilizes an ADCC-mediating mAb as a
mechanism of action. Studies using patient samples during
treatment with Herceptin, Rituximab, and Cetuximab have
correlated an FcγRIIIa158v receptor genotype with better
response to therapy [46–48] .T h er e s p o n s eo fF c γRIIIa158v
NK cells in an in vitro assay of ADCC against antibody-
coated tumor cells can be used as a predictor for patient
response to therapy [49]. The role of Fc receptor polymor-
phisms on the response to immunocytokine in comparison4 Journal of Biomedicine and Biotechnology
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Figure 1: Immunocytokine facilitates adhesion of NK cells to tumor cells. This ﬁgure, adapted from Buhtoiarov et al. [36], shows the
adhesion of M21 human melanoma tumor cells to NKL human NK cells after coincubation for 30 minutes. Tumor cells were prelabeled
with CFSE, and NK cells were prelabeled with BODIPY and coincubated in medium alone, with hu14.18 (mAb) alone, soluble IL2, hu14.18
+ soluble IL2, or hu14.18-IL2immunocytokine (IC).The percentage of cells that had formed conjugates was deﬁned as double positive cells
as determined by ﬂow cytometry.
with mAb remains to be answered. A recent study from our
laboratory [12] evaluated patient samples from our COG
phase II anti-GD2 IC trial for FcγRIIIa genotypes [40].
This study only had two patients with an FcγRIIIa158v/v
genotype and was therefore inconclusive. The identiﬁcation
ofFcγR polymorphisms that aﬀect clinical responses to mAb
therapymay suggestanewcriterionformore tailoredpatient
selection for mAb therapy. The importance of FcγRIIIa
polymorphisms in IC-induced anti-tumor responses will be
of considerable interest because of the involvement of the
IL2R.
7.KIRs andthe Responseto mAbs and ICs
An important factor in NK-mediated therapy is the intrinsic
ability for NK cells to respond to stimuli. The licensing
hypothesis of NK cell function was developed after the
observation that NK cells from mice lacking MHC-I, an
important NK inhibitory ligand, respond poorly [50]. The
intricate system of killer cell immunoglobulin-like receptors
(KIRs) in humans and Ly-49 receptors in mice recognizes
normally expressed MHC-I antigens on neighboring cells
and inhibit NK cell eﬀector functions [51]. According to the
licensing hypothesis, an NK cell that does not encounter a
ligand for one of its KIR or Ly49 inhibitory receptors during
development is functionally deﬁcient [50]. However, KIR
and Ly49genesare inheritedon diﬀerentchromosomes from
MHC, and therefore many individuals and mouse strains
have at least one KIR or Ly49 that lacks a corresponding
ligand [51]. These individuals and mouse strains have at
least one population of functionally deﬁcient NK cells
[50], reﬂecting the NK population that contains the KIR
receptor corresponding tothe KIR/KIR-Lmismatch. Clinical
studies evaluating KIR/KIR-L matching have estimated that
∼60% of people have at least one KIR for which they
lack a corresponding receptor and are therefore KIR/KIR-L
mismatched for at least one locus [51].
Some preclinical studies have challenged the importance
of licensing in certain models. Orr et al. evaluated the
response of licensed versus unlicensed NK cells in response
to murine cytomegalovirus (MCMV). C57Bl/6 mice have
a “licensed” subset of NK cells expressing Ly49C/I, the
receptor for H2b and “unlicensed” NK cells expressing anJournal of Biomedicine and Biotechnology 5
activating Ly49H. After infection of B6 mice with MCMV,
a virus for which NK cell function is necessary for control,
LY49C/Ineg Ly49H+ (“unlicensed”) NK cells were able to
respond toinfection [52].This paperelegantly demonstrated
that unlicensed NK cells still maintain some functionality to
activating signals, although their eﬀector responses are still
less powerful than that of licensed NK cells.
New data suggest that “licensing” may not be a process
restricted to NK cell development but is actually a contin-
uous process that even mature NK cells use to respond to
their environment [53, 54]. Recently, two separate reports
compared adoptive transfer studies between wild type (WT)
and β2m knockout (MHC-I deﬁcient) mice to show that
mature NK cells become hyporesponsive when they are put
into an environment lacking MHC and vice versa [53, 54].
In these studies, only NK cells expressing an inhibitory Ly49
for which there was a cognate MHC-I ligand present could
respond in the new surroundings. These studies suggest
that “licensing” is a continuous (rather than absolute)
mechanism that NK cells use to judge and appropriately
respond to a changing environment.
While studies using murine models have been valuable
in dissecting the potential factors aﬀecting NK cell respon-
siveness, some observations of better anti-tumor responses
by patients that are self-KIR/KIR-L mismatched have been
made at multiple institutions [12, 55, 56]. Two studies
evaluated anti-tumor responses in pediatric cancer patients
following autologousstem cell transplant [55, 56].These two
independent studies both observed an association between
disease-free survival and autologous KIR/KIR-L mismatch.
Our laboratory recently evaluated the KIR/KIR-L status [12]
of neuroblastoma patient samples from our COG phase
II study of the anti-GD2-IC, hu14.18-IL2 [40]. In this
study, we observed a better response to IC in patients that
were KIR/KIR-L mismatched. These data suggest that the
“unlicensed” NK cells in these patients were still involved in
mediating the observed antitumor eﬀect after IC treatment,
consistent with some retained NK function by “unlicenced”
NK cells. Previous reports have suggested that KIR-deﬁcient
NK cells have impaired responses to CD16-mediated stimu-
lation [57]. In this study using NK cells from healthy donors,
fewer KIR-deﬁcient CD56dim NK cells produced IFNγ or
upregulated CD107a in response to either antibody-coated
tumor cells or plate bound anti-CD16. However, our study
using patient samples [12] and evaluating response to IC
rather than naked mAb warrants a closer examination of NK
cell “licensing” in the context of IC-mediated ADCC.
8.Conclusions
In the relatively short time since the ﬁrst description of NK
c e l l s ,j u s to v e r3 5y e a r sa g o[ 58], we have learned a great
deal about their function. This knowledge has allowed us to
designtherapeuticstrategies thatutilizethepowerful eﬀector
mechanisms of NK cells for multiple malignancies [6–8, 40].
Our understanding of NK cells, NK cell eﬀector responses,
and the signals that drive them, continues to expand. NK
cells are capable of eliminating tumor cells coated with an
IgG antibody in vitro and in some patients, and activation of
NK cells with cytokines such as IL2 increases the anti-tumor
eﬀect [14, 15, 24, 46]. This approach has led to successful
therapeutic mAbs for certain tumors but still do not elicit a
response in all patients [38].
Our continued understanding of the factors that aﬀect
the response to Ab-coated tumor cells in the tumor
environment is important for the creation of the next-
generation mAbs and therapeutic strategies. Important
intrinsic factors that aﬀect NK cell responsiveness to Ab-
coated tumor cells includethe expressed variants of FcγRIIIa
and the intrinsic ability of individual NK cell subsets to
respond to stimuli due to their “licensing” status [12, 50].
Separate factors include the mass of tumor present when
immunotherapy is given, the activation state of the eﬀector
cells mediating ADCC, and potential other receptor-ligand
interactions that inﬂuence the synapse formed between
NK and tumor cells. Next-generation immunocytokines
may have a functional advantage over traditional mAbs
in activation of certain NK cell subsets because of the
contribution of cytokine receptors [33, 36, 37].
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